These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10220610)

  • 21. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacy and Therapeutics committee. Cost-containment considerations.
    Hochla PK; Tuason VB
    Arch Intern Med; 1992 Sep; 152(9):1773-5. PubMed ID: 1520043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding, creating, and working with formulary systems.
    Quinn CE; Barisano A
    Am J Manag Care; 1999 Oct; 5(10):1311-7; quiz 1318-9. PubMed ID: 10622996
    [No Abstract]   [Full Text] [Related]  

  • 26. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 27. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 28. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 29. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
    Kazi DS; Penko J; Ollendorf DA; Coxson PG; Bibbins-Domingo K
    Ann Intern Med; 2018 Jun; 168(12):896-898. PubMed ID: 29610832
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The bleeding edge of decision making in managed health care--Kaiser-Permanente's model for formulary development.
    Campen D
    Value Health; 2002; 5(5):383-9. PubMed ID: 12201855
    [No Abstract]   [Full Text] [Related]  

  • 33. Applying decision analysis to pharmacy management and practice decisions.
    Barr JT; Schumacher GE
    Top Hosp Pharm Manage; 1994 Jan; 13(4):60-71. PubMed ID: 10130685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S38-40. PubMed ID: 10220594
    [No Abstract]   [Full Text] [Related]  

  • 36. Prospective reimbursement and DRGs: implications for formulary management.
    Enright SM
    Hosp Formul; 1983 Oct; 18(10):989-90, 999-1000. PubMed ID: 10310246
    [No Abstract]   [Full Text] [Related]  

  • 37. Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors.
    Blumenthal DM; Goldman D; Jena AB
    JAMA Cardiol; 2017 Oct; 2(10):1063-1064. PubMed ID: 28854318
    [No Abstract]   [Full Text] [Related]  

  • 38. Evolution and cost trends of antihypertensive and hypolipidaemic drug treatment in France.
    Marques-Vidal P; Montaye M; Ruidavets JB; Amouyel P; Ferrières J
    Cardiovasc Drugs Ther; 2003 Mar; 17(2):175-89. PubMed ID: 12975599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 40. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
    Lee TH
    Am Heart J; 1999 May; 137(5):S67-70. PubMed ID: 10220600
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.